scholarly journals Cognitive function and discontinuation of adjuvant hormonal therapy in older breast cancer survivors: CALGB 369901 (Alliance)

2017 ◽  
Vol 165 (3) ◽  
pp. 677-686 ◽  
Author(s):  
Shirley M. Bluethmann ◽  
Catherine M. Alfano ◽  
Jonathan D. Clapp ◽  
George Luta ◽  
Brent J. Small ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cognitive Function ◽  
Cancer Survivors ◽  
Hormonal Therapy ◽  
Breast Cancer Survivors ◽  
Adjuvant Hormonal Therapy

scholarly journals Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review

2012 ◽  
Vol 134 (2) ◽  
pp. 459-478 ◽  
Author(s):  
Caitlin C. Murphy ◽  
L. Kay Bartholomew ◽  
Melissa Y. Carpentier ◽  
Shirley M. Bluethmann ◽  
Sally W. Vernon
Keyword(s):  
Breast Cancer ◽  
Systematic Review ◽  
Clinical Practice ◽  
Cancer Survivors ◽  
Hormonal Therapy ◽  
Breast Cancer Survivors ◽  
Adjuvant Hormonal Therapy

scholarly journals Understanding Breast Cancer Survivors’ Beliefs and Concerns About Adjuvant Hormonal Therapy: Promoting Adherence

2017 ◽  
Vol 33 (2) ◽  
pp. 436-439 ◽  
Author(s):  
Alejandra Hurtado-de-Mendoza ◽  
Roxanne E. Jensen ◽  
Yvonne Jennings ◽  
Vanessa B. Sheppard
Keyword(s):  
Breast Cancer ◽  
Cancer Survivors ◽  
Hormonal Therapy ◽  
Breast Cancer Survivors ◽  
Adjuvant Hormonal Therapy

scholarly journals Cancer-Related Cognitive Outcomes Among Older Breast Cancer Survivors in the Thinking and Living With Cancer Study

2018 ◽  
Vol 36 (32) ◽  
pp. 3211-3222 ◽  
Author(s):  
Jeanne S. Mandelblatt ◽  
Brent J. Small ◽  
Gheorghe Luta ◽  
Arti Hurria ◽  
Heather Jim ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cognitive Function ◽  
Cancer Survivors ◽  
Hormonal Therapy ◽  
Breast Cancer Survivors ◽  
Apoe Genotype ◽  
Treatment Decision ◽  
Cognitive Outcomes ◽  
Treatment Decision Making ◽  
Survivorship Care Planning

Purpose To determine treatment and aging-related effects on longitudinal cognitive function in older breast cancer survivors. Methods Newly diagnosed nonmetastatic breast cancer survivors (n = 344) and matched controls without cancer (n = 347) 60 years of age and older without dementia or neurologic disease were recruited between August 2010 and December 2015. Data collection occurred during presystemic treatment/control enrollment and at 12 and 24 months through biospecimens; surveys; self-reported Functional Assessment of Cancer Therapy-Cognitive Function; and neuropsychological tests that measured attention, processing speed, and executive function (APE) and learning and memory (LM). Linear mixed-effects models tested two-way interactions of treatment group (control, chemotherapy with or without hormonal therapy, and hormonal therapy) and time and explored three-way interactions of ApoE (ε4+ v not) by group by time; covariates included baseline age, frailty, race, and cognitive reserve. Results Survivors and controls were 60 to 98 years of age, were well educated, and had similar baseline cognitive scores. Treatment was related to longitudinal cognition scores, with survivors who received chemotherapy having increasingly worse APE scores ( P = .05) and those initiating hormonal therapy having lower LM scores at 12 months ( P = .03) than other groups. These group-by-time differences varied by ApoE genotype, where only ε4+ survivors receiving hormone therapy had short-term decreases in adjusted LM scores (three-way interaction P = .03). For APE, the three-way interaction was not significant ( P = .14), but scores were significantly lower for ε4+ survivors exposed to chemotherapy (−0.40; 95% CI, −0.79 to −0.01) at 24 months than ε4+ controls (0.01; 95% CI, 0.16 to 0.18; P < .05). Increasing age was associated with lower baseline scores on all cognitive measures ( P < .001); frailty was associated with baseline APE and self-reported decline ( P < .001). Conclusion Breast cancer systemic treatment and aging-related phenotypes and genotypes are associated with longitudinal decreases in cognitive function scores in older survivors. These data could inform treatment decision making and survivorship care planning.

scholarly journals Providers’ perspectives on adherence to hormonal therapy in breast cancer survivors. Is there a role for the digital health feedback system?

2018 ◽  
Vol 9 (2) ◽  
pp. 175-184 ◽  
Author(s):  
Alejandra Hurtado-de-Mendoza ◽  
Mark L. Cabling ◽  
Asma Dilawari ◽  
Jeanine Warisse Turner ◽  
Nicole C. Fernández ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Survivors ◽  
Hormonal Therapy ◽  
Breast Cancer Survivors ◽  
Digital Health ◽  
Feedback System

scholarly journals Adherence and persistence to adjuvant hormonal therapy in early stage breast cancer patients: A population-based retrospective cohort study in Israel.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. e12051-e12051
Author(s):  
Tal Sella ◽  
Gabriel Chodick
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Hormonal Therapy ◽  
Breast Cancer Survivors ◽  
Early Stage ◽  
Population Based ◽  
Early Stage Breast Cancer ◽  
Adjuvant Hormonal Therapy ◽  
Breast Cancer Patients ◽  
Suboptimal Adherence

e12051 Background: Adjuvant hormonal therapy has been consistently proven to improve multiple outcomes in early breast cancer. Nonetheless, data on rates of adherence and persistence with therapy outside West Europe and North America are scarce. We assessed the adherence and persistence with adjuvant hormonal in a retrospective population based cohort of breast cancer survivors in Maccabi Health Services (MHS), Israel. Methods: We identified women who were diagnosed with breast cancer and initiated adjuvant hormonal therapy between January 2000 and November 2008. Subjects were followed retrospectively from first dispensed tamoxifen or aromatase inhibitor (AI) and up to the earliest of the following events: disease recurrence (indicated by surgery, radiotherapy, chemotherapy or other related therapies), leaving MHS, death, or completion of 5 years of treatment. Discontinuation of therapy was defined as a 180-day or longer treatment gap. Adherence with therapy was assessed using proportion of days covered (PDC) during follow-up period. Survival analysis was used to determine the effect of adherence on all-cause mortality. Results: A total of 4178 women with breast cancer were followed for a median 7.8 years. Over 90% of patients received tamoxifen as the initial hormonal agent. Mean PDC was 84% with lower rates associated with younger age, smoking status, comorbidities and year of diagnosis. Residential area did not affect adherence. Differences were not found. Discontinuation of therapy occurred in 23% of study patients. Among persistent patients, 70% were optimally adherent with therapy (PDC>=80%). Association between adherence with therapy and survival is investigated. Conclusions: Adherence to adjuvant hormonal therapy among Israeli breast cancer patients with national health insurance is high in comparison to international reports. Nevertheless, suboptimal adherence was identified among younger (<45y) patients. Because of the efficacy of hormonal therapy in preventing recurrence and death in women with early-stage breast cancer, interventions are necessary to identify and prevent suboptimal adherence among high risk subgroups.

Sign in / Sign up

Export Citation Format

Share Document